Outlook Therapeutics is trading at $0.72, up +5.82%, with the move appearing aligned with broader pre-market risk appetite.
- No new company-specific announcement was identified for September 17, 2026; the latest releases were investor discussions on September 10 and September 11.
- The S&P 500, Nasdaq Composite, and Dow Jones were all higher.
- The prior Federal Reserve hike and ongoing rate sensitivity remain relevant macro drivers.